Literature DB >> 6134542

Effect of the benzodiazepine antagonist Ro 15-1788 on flunitrazepam-induced sleep changes.

J M Gaillard, R Blois.   

Abstract

1 The modifications of human sleep induced by benzodiazepines, and particularly by flunitrazepam, are complex. Stage 4 and paradoxical sleep are both decreased; however, these two effects have a different evolution during and after single or short-term drug administration. 2 The benzodiazepine antagonist Ro 15-1788 also tends to depress stage 4, but with immediate recovery in the post-drug night, and does not modify paradoxical sleep. 3 In combined administration, this drug totally reverses the hypnogenic effect of flunitrazepam, as well as its effect on paradoxical sleep but not the decrease of slow wave sleep. 4 Some of the benzodiazepine-induced alterations of sleep may be related to receptors different from central benzodiazepine receptors, or to mechanisms not directly connected to this type of receptors.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6134542      PMCID: PMC1427719          DOI: 10.1111/j.1365-2125.1983.tb02086.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  17 in total

1.  Temporal organization of human sleep: general trends of sleep stages and their ultradian cyclic components.

Authors:  J M Gaillard
Journal:  Encephale       Date:  1979       Impact factor: 1.291

2.  Comparison of two muscle relaxant drugs on human sleep: diazepam and parachlorophenylgaba.

Authors:  J M Gaillard
Journal:  Acta Psychiatr Belg       Date:  1977 May-Jun

3.  Flunitrazepam, an investigational hypnotic drug: sleep laboratory evaluations.

Authors:  E O Bixler; A Kales; C R Soldatos; J D Kales
Journal:  J Clin Pharmacol       Date:  1977-10       Impact factor: 3.126

4.  EEG sleep studies of insomniacs under flunitrazepam treatment.

Authors:  J M Gaillard; R Tissot
Journal:  Int Pharmacopsychiatry       Date:  1975

5.  Flurazepam effects on slow-wave sleep: stage 4 suppressed but number of delta waves constant.

Authors:  I Feinberg; G Fein; J M Walker; L J Price; T C Floyd; J D March
Journal:  Science       Date:  1977-11-25       Impact factor: 47.728

6.  Specific benzodiazepine receptors in rat brain characterized by high-affinity (3H)diazepam binding.

Authors:  C Braestrup; R F Squires
Journal:  Proc Natl Acad Sci U S A       Date:  1977-09       Impact factor: 11.205

7.  Flunitrazepam (Ro 5-4200) and sleep cycle in normal subjects.

Authors:  J M Monti; H Altier
Journal:  Psychopharmacologia       Date:  1973-10-15

8.  Principles of automatic analysis of sleep records with a hybrid system.

Authors:  J M Gaillard; R Tissot
Journal:  Comput Biomed Res       Date:  1973-02

9.  Activity of the hypnotics, flunitrazepam and triazolam, in man.

Authors:  A N Nicholson; B M Stone
Journal:  Br J Clin Pharmacol       Date:  1980-02       Impact factor: 4.335

10.  [Increase in local cerebral glucose consumption in the choroid plexus during slow wave sleep in the cat].

Authors:  P Bobillier; S Seguin; F Petitjean; C Buda; D Salvert; M Janin; G Chouvet; C Souchier; M Jouvet
Journal:  C R Seances Acad Sci D       Date:  1980-07-07
View more
  15 in total

Review 1.  Hypnotics and sleep physiology: a consensus report. European Sleep Research Society, Committee on Hypnotics and Sleep Physiology.

Authors:  A A Borbély; T Akerstedt; O Benoit; F Holsboer; I Oswald
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  1991       Impact factor: 5.270

2.  The effects of the benzodiazepine antagonist Ro 15-1788 on psychophysiological performance and subjective measures in normal subjects.

Authors:  A Higgitt; M Lader; P Fonagy
Journal:  Psychopharmacology (Berl)       Date:  1986       Impact factor: 4.530

3.  Does the benzodiazepine antagonist Ro 15-1788 antagonize the action of ethanol?

Authors:  U Klotz; G Ziegler; B Rosenkranz; G Mikus
Journal:  Br J Clin Pharmacol       Date:  1986-11       Impact factor: 4.335

4.  Chronic sleep disorders in survivors of the acute respiratory distress syndrome.

Authors:  Christie M Lee; Margaret S Herridge; Jonathan Y Gabor; Catherine M Tansey; Andrea Matte; Patrick J Hanly
Journal:  Intensive Care Med       Date:  2008-09-18       Impact factor: 17.440

5.  Pharmacokinetics of the new benzodiazepine antagonist Ro 15-1788 in man following intravenous and oral administration.

Authors:  G Roncari; W H Ziegler; T W Guentert
Journal:  Br J Clin Pharmacol       Date:  1986-10       Impact factor: 4.335

6.  Cerebral-activating (EEG) properties of two inverse agonists and of an antagonist at the benzodiazepine receptor in the rat.

Authors:  V Santucci; M Fournier; P Worms; P Keane; K Bizière
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1989-07       Impact factor: 3.000

7.  The effect of the benzodiazepine antagonist, flumazenil, on psychometric performance in acute ethanol intoxication in man.

Authors:  T G Clausen; J Wolff; P Carl; A Theilgaard
Journal:  Eur J Clin Pharmacol       Date:  1990       Impact factor: 2.953

8.  Pharmacokinetics of the selective benzodiazepine antagonist Ro 15-1788 in man.

Authors:  U Klotz; G Ziegler; I W Reimann
Journal:  Eur J Clin Pharmacol       Date:  1984       Impact factor: 2.953

9.  Benzodiazepine overdose: are specific antagonists useful.

Authors:  C H Ashton
Journal:  Br Med J (Clin Res Ed)       Date:  1985-03-16

10.  Lack of effect of the benzodiazepine antagonist flumazenil (Ro 15-1788) on the performance of healthy subjects during experimentally induced ethanol intoxication.

Authors:  A Flückiger; D Hartmann; B Leishman; W H Ziegler
Journal:  Eur J Clin Pharmacol       Date:  1988       Impact factor: 2.953

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.